ChemoCentryx Inc.Find Ratings Reports
CHEMOCENTRYX INC's gross profit margin for the third quarter of its fiscal year 2019 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. CHEMOCENTRYX INC is extremely liquid. Currently, the Quick Ratio is 3.09 which clearly shows the ability to cover any short-term cash needs. CCXI managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 188.10% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY19||Q3 FY18|
|Net Sales ($mil)||10.58||8.98|
|Net Income ($mil)||-12.86||-10.89|
|Balance Sheet||Q3 FY19||Q3 FY18|
|Cash & Equiv. ($mil)||170.93||173.12|
|Total Assets ($mil)||212.32||190.76|
|Total Debt ($mil)||22.14||14.73|
|Profitability||Q3 FY19||Q3 FY18|
|Gross Profit Margin||-127.53||-126.9|
|Return on Assets||-23.9||6.53|
|Return on Equity||-82.03||58.09|
|Debt||Q3 FY19||Q3 FY18|
|Share Data||Q3 FY19||Q3 FY18|
|Shares outstanding (mil)||58.25||50.43|
|Div / share||0.0||0.0|
|Book value / share||1.06||0.43|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1281585.0||448151.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 46.70 indicates a significant premium versus the S&P 500 average of 3.65 and a significant premium versus the subsector average of 8.00. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, CHEMOCENTRYX INC proves to trade at a premium to investment alternatives.
|CCXI NM||Peers 27.52||CCXI NM||Peers 34.20|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CCXI's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CCXI's P/CF is negative making the measure meaningless.
|CCXI NM||Peers 17.80||CCXI NA||Peers 0.89|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
CCXI's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CCXI 46.70||Peers 8.00||CCXI -468.00||Peers 94.35|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CCXI is trading at a significant premium to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, CCXI is expected to significantly trail its peers on the basis of its earnings growth rate.
|CCXI 81.58||Peers 107.59||CCXI -60.59||Peers 147.32|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CCXI is trading at a discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
CCXI significantly trails its peers on the basis of sales growth.